Welcome to our dedicated page for Cyclerion Therapeutics SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cyclerion Therapeutics filings document material-event disclosures for a clinical-stage biopharmaceutical company developing neuropsychiatric therapeutics. Recent Form 8-K filings cover CYC-126 development updates, a clinical advisory board, and material agreements tied to technology for neuropsychiatric disorders and anesthetic delivery systems.
The company’s SEC records also describe its common stock listing under CYCN, shareholder voting results, director elections, auditor ratification, executive-compensation votes, governance matters, and exhibit-based press-release disclosures. The filings provide formal records of Cyclerion’s licensing arrangements, collaboration rights, capital structure, and transition from legacy sGC stimulator assets toward a neuropsychiatric pipeline.
Cyclerion Therapeutics (CYCN) reported Q3 2025 results. Revenue was $875,000, up from $194,000 a year ago, driven mainly by $800,000 from an Akebia material purchase. The company posted a net loss of $976,000 (vs. $723,000), while year‑to‑date net loss improved to $2.7 million from $3.6 million.
Cash and cash equivalents were $4.6 million at September 30, 2025. Stockholders’ equity stood at $9.5 million. The company raised capital through a private placement (499,998 shares for approximately $1.375 million gross) and an ATM program (604,166 shares for $1.8 million net in Q3), with an additional 111,054 ATM shares sold for about $0.3 million after quarter‑end. Shares outstanding were 3,925,314 as of November 10, 2025.
Cyclerion signed a Patent License Agreement with MIT in September 2025 related to neuropsychiatric disorders, with up to $4.4 million in potential milestones and low single‑digit royalties. The olinciguat option expired without a license. Management states cash is expected to fund operations into Q2 2026, yet there is substantial doubt about the company’s ability to continue as a going concern absent additional financing.
Cyclerion Therapeutics filed an amended annual report (10-K/A) to add a missing “Critical Audit Matter” paragraph to the auditor’s report; the financial statements and notes are otherwise unchanged from the original filing.
For 2024, Cyclerion reported revenue of $2,000 thousand (license $1,750 thousand and option $250 thousand), operating expenses of $5,628 thousand, and a net loss of $3,057 thousand, narrower than 2023. Cash and cash equivalents were $3,232 thousand as of December 31, 2024. The auditor included a going concern emphasis, and management disclosed that cash is expected to fund operations through mid-2025, indicating substantial doubt about the company’s ability to continue as a going concern.
The amended audit report identifies the assessment of impairment indicators for a $5,350 thousand investment in Tisento Therapeutics Holdings Inc. as a critical audit matter; no impairment was recognized as of December 31, 2024. Under an amended Akebia license, Cyclerion received $1,250 thousand in December 2024 and is due $500 thousand in September 2025 in amendment payments, with eligibility for additional milestones. Shares outstanding were 2,710,096 as of February 28, 2025; 2,545,922 were outstanding as of December 31, 2024.
Cyclerion Therapeutics, Inc. entered into a Patent License Agreement with the Massachusetts Institute of Technology granting Cyclerion an exclusive worldwide license to develop and commercialize products using certain technology for treating neuropsychiatric disorders, such as depression, in humans. Cyclerion will pay MIT a nominal upfront amount and MIT may receive up to $4.4 million in development, regulatory and sales milestone payments, plus tiered royalties in low single-digit percentages on future net sales of licensed products.
Cyclerion will be responsible for development, regulatory approvals and commercialization of licensed products, while MIT will handle filing, prosecution and maintenance of the licensed patent rights in cooperation with Cyclerion. The license term runs until specified patent rights expire, subject to earlier termination under the agreement. Cyclerion also announced its relaunch as a neuropsychiatric company and furnished a press release and investor presentation describing the license and strategic relaunch.
Cyclerion Therapeutics, Inc. entered into a Patent License Agreement with the Massachusetts Institute of Technology granting Cyclerion an exclusive worldwide license to develop and commercialize products using certain technology for treating neuropsychiatric disorders, such as depression, in humans. Cyclerion will pay MIT a nominal upfront amount and MIT may receive up to $4.4 million in development, regulatory and sales milestone payments, plus tiered royalties in low single-digit percentages on future net sales of licensed products.
Cyclerion will be responsible for development, regulatory approvals and commercialization of licensed products, while MIT will handle filing, prosecution and maintenance of the licensed patent rights in cooperation with Cyclerion. The license term runs until specified patent rights expire, subject to earlier termination under the agreement. Cyclerion also announced its relaunch as a neuropsychiatric company and furnished a press release and investor presentation describing the license and strategic relaunch.
Cyclerion Therapeutics, Inc. (CYCN) reported that Chief Financial Officer Rhonda M. Chicko was granted an option to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The grant, reported with a transaction date of 08/07/2025, is under the 2019 Equity Incentive Plan. Of the 25,000 shares, 8,750 are immediately exercisable and 16,250 vest in monthly installments beginning August 31, 2025 and ending February 28, 2028, subject to continued service. The option expires August 6, 2035, and the reporting person is shown as the direct beneficial owner of the 25,000 option shares following the transaction.